Vor Biopharma Inc. (VOR): Debts to Book Capitalization

Vor Biopharma Inc. (VOR) is implementing advanced gene editing to protect stem cells from aggressive treatment. This price chart reflects the dynamics of the asset, which is currently valued at 0.00. The business is focusing on early-stage trials of its leukemia platforms while preserving capital for research. The company's developments minimize risks during bone marrow transplantation, ensuring therapy safety.

vorbio.com (VOR): Debt to Net Assets Ratio from 07/04/2022 to 10/27/2026

Vor Biopharma, Inc. (VOR) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Vor Biopharma Inc.|VOR - Consensus Target

- market capitalization data:

Market Capitalization Vor Bio Inc.|VOR - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Vor Biopharma|VOR - Accounting Value of Company|Market Cap to Net Assets Ratio vorbio.com|VOR - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Vor Biopharma Inc.|VOR - Long-Term Debt to Equity|Short-Term Debt to Equity Vor Bio|VOR - Company Debts|Debt to Book Capitalization Ratio Vor Bio Inc.

Summary company analytics:Vor Biopharma Inc. - VOR

Reducing the debt load minimizes financial risks, which is critical for Vor Biopharma Inc. (VOR), as the company utilizes outsourcing for production and clinical trials to eliminate capital expenditures. The ratio of total liabilities to the book value of equity, illustrated on this financial leverage trend chart, demonstrates the business's degree of dependence on borrowed funds and its overall resilience to rising interest rates.

Who Vor Biopharma Inc. competes with